# Center for Biologics Evaluation and Research (CBER)

Type: organization

Source: GetYourBrief — https://getyourbrief.com/entity/center-for-biologics-evaluation-and-research-cber-organization
Canonical HTML page: https://getyourbrief.com/entity/center-for-biologics-evaluation-and-research-cber-organization

## Timeline

- **2026-Q4 (expected)**: First Approvals — Anticipated first wave of gene therapy approvals under the new streamlined framework.
- **2026-Q4**: Expected Finalization — Anticipated period for final guidance after public comment and review.
- **2026-02-24**: New System Proposed — FDA formally announces the proposed framework for customized drug approvals.
- **2026-02-23**: Expedited Pathway Formalized — FDA announces the formal implementation of quicker paths for gene therapy via surrogate endpoints.
- **2026-02-23**: Quicker Path Formalized — Official rollout of the streamlined regulatory framework for gene therapy approvals.
- **2026-02-23**: Framework Formalized — FDA officially announces the 'plausible mechanism' framework for ultra-rare disease therapies.
- **2025-11-15**: Draft Guidance Issued — FDA releases draft guidance on using surrogate endpoints for gene therapy accelerated approval.
- **2025-06-15**: CBER Staffing Surge — FDA completes hiring of 100+ new reviewers dedicated to biologics and gene therapy.
- **2024-05-15**: START Pilot Launch — FDA initiates a pilot program for Support for clinical Trials Advancing Rare disease Therapeutics.
- **2023-09-29**: START Pilot Launch — FDA launches the Support for clinical Trials Advancing Rare disease Therapeutics (START) pilot program.
- **2023-09-29**: START Program — CBER launches the Support for clinical Trials Advancing Rare disease Therapeutics pilot.
- **2023-05-01**: START Pilot Program — FDA launches the Support for clinical Trials Advancing Rare disease Therapeutics pilot.
- **2023-03-01**: CBER Reorganization — The Office of Tissues and Advanced Therapies is elevated to a 'Super Office' to handle CGT volume.
- **2021-12-01**: ASO Guidance — FDA issues initial draft guidance for ASO products for ultra-rare diseases.
- **2017-12-19**: Luxturna Approval — FDA approves the first gene therapy for an inherited disease, setting the initial regulatory precedent.

## Recent coverage (4 stories, network-wide)

### FDA Proposes Streamlined Framework for N-of-1 and Rare Disease Therapies
2026-02-24 03:18:04 · Sector: health · Sentiment: Positive · Impact: 8/10 · Sources: 2

The FDA has unveiled a proposed regulatory pathway designed to accelerate the approval of customized, patient-specific therapies for ultra-rare diseases. This initiative aims to shift from traditional population-based clinical trials to a data-driven model that supports individualized genomic medicine.
Full story: https://gethealthbrief.com/story/fda-customized-rare-disease-drug-framework

### FDA Accelerates Gene Therapy Approvals via 'Plausible Mechanism' Framework
2026-02-23 22:39:41 · Sector: bio · Sentiment: Positive · Impact: 8/10 · Sources: 8

The FDA has officially introduced a streamlined regulatory pathway for gene therapies, allowing for accelerated approval based on 'plausible mechanisms' and biomarkers rather than traditional clinical outcomes. This landmark shift aims to fast-track treatments for ultra-rare diseases where traditional large-scale clinical trials are statistically impossible.
Full story: https://getbiobrief.com/story/fda-quicker-path-gene-therapies-accelerated-approval

### FDA Accelerates Gene Therapy Approvals with New Regulatory Framework
2026-02-23 22:39:08 · Sector: health · Sentiment: Positive · Impact: 8/10 · Sources: 8

The FDA has launched a streamlined regulatory pathway designed to expedite the development and review of gene therapies, particularly for rare diseases. This initiative marks a significant shift toward using surrogate endpoints and flexible trial designs to bring life-saving treatments to market faster.
Full story: https://gethealthbrief.com/story/fda-quicker-path-gene-therapies-regulation

### FDA Accelerates Gene Therapy Approvals via New Regulatory Framework
2026-02-23 22:35:23 · Sector: legal · Sentiment: Positive · Impact: 8/10 · Sources: 8

The U.S. Food and Drug Administration has established a streamlined regulatory pathway to expedite the development and review of gene therapies. This initiative focuses on leveraging surrogate endpoints and platform technologies to bring life-altering treatments for rare diseases to market faster.
Full story: https://getlegalbrief.com/story/fda-expedited-gene-therapy-pathway

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.